Home › Melanoma
Melanoma clinical trials recruiting in the U.S.
196 studies for Melanoma are recruiting participants at sites across the United States.
Melanoma is the most serious type of skin cancer. Most have a black or black-blue area. Learn the 'ABCDE' of what to watch for and treatment options.
Cities with the most studies
- Houston, TX59 studies
- New York City, NY38 studies
- Los Angeles, CA34 studies
- Nashville, TN32 studies
- Pittsburgh, PA31 studies
- Boston, MA25 studies
- Philadelphia, PA23 studies
- San Francisco, CA22 studies
- Salt Lake City, UT21 studies
- Columbus, OH21 studies
- Atlanta, GA21 studies
- St. Louis, MO20 studies
- Durham, NC20 studies
- Dallas, TX20 studies
- Arlington, VA20 studies
- Denver, CO19 studies
- Tampa, FL19 studies
- San Diego, CA18 studies
- Aurora, CO18 studies
- Washington, DC17 studies
- Cincinnati, OH17 studies
- Grand Rapids, MI17 studies
- Seattle, WA17 studies
- Edison, NJ16 studies
- Queens, NY16 studies
- Rochester, MN16 studies
- Jacksonville, FL16 studies
- Chicago, IL15 studies
- San Antonio, TX15 studies
- Portland, OR15 studies
- Madison, WI15 studies
- Orlando, FL15 studies
- Orange, CA14 studies
- Cleveland, OH13 studies
- Omaha, NE12 studies
- Ann Arbor, MI12 studies
- Minneapolis, MN12 studies
- Austin, TX11 studies
- Detroit, MI11 studies
- Richmond, VA11 studies
By state
- Alabama12 studies
- Alaska5 studies
- Arizona26 studies
- Arkansas13 studies
- California70 studies
- Colorado32 studies
- Connecticut14 studies
- Delaware6 studies
- District of Columbia7 studies
- Florida55 studies
- Georgia23 studies
- Hawaii3 studies
- Idaho8 studies
- Illinois22 studies
- Indiana14 studies
- Iowa12 studies
- Kansas15 studies
- Kentucky21 studies
- Louisiana9 studies
- Maine4 studies
- Maryland24 studies
- Massachusetts28 studies
- Michigan31 studies
- Minnesota29 studies
- Mississippi3 studies
- Missouri22 studies
- Montana8 studies
- Nebraska16 studies
- Nevada6 studies
- New Hampshire6 studies
- New Jersey24 studies
- New Mexico11 studies
- New York50 studies
- North Carolina30 studies
- North Dakota9 studies
- Ohio40 studies
- Oklahoma14 studies
- Oregon15 studies
- Pennsylvania47 studies
- Rhode Island5 studies
- South Carolina10 studies
- South Dakota6 studies
- Tennessee39 studies
- Texas77 studies
- Utah26 studies
- Vermont5 studies
- Virginia34 studies
- Washington25 studies
- West Virginia7 studies
- Wisconsin20 studies
- Wyoming3 studies
Recently updated studies
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07519655Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of Melanoma
RecruitingObservational studyHealthy volunteers welcome
4 Weeks – 99 Years · All sexes · Updated Sep 28, 2026 · NCT00040352A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06961006Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06548789A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06246916DESTINY-PANTUMOUR04
RecruitingObservational study
Ages 18 to 130 · All sexes · Updated Sep 25, 2026 · NCT07124000A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06172478BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05136196Pan-tumor MRD Study
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06605404A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
RecruitingPhase 2
Up to age 25 · All sexes · Updated Sep 24, 2026 · NCT07621614Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
RecruitingPhase 3
Ages 18 to 70 · All sexes · Updated Sep 24, 2026 · NCT05727904Comparing the Effectiveness of Less Invasive Procedures With the Current Standard of Care for the Treatment of Older Adults With Early-Stage Melanoma
RecruitingPhase 3
Ages 75 and older · All sexes · Updated Sep 24, 2026 · NCT07068074Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
Recruiting
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07661966Intratumoral N17350 in Advanced Solid Tumors
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07339176A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Sep 22, 2026 · NCT06066138Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
RecruitingPhase 1/2
Ages 18 to 99 · All sexes · Updated Sep 22, 2026 · NCT06814496Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT06529822A Pilot Study of ctDNA-Guided Immune Checkpoint Inhibitor Duration in Patients With Advanced Melanoma.
Recruiting
Ages 18 to 90 · All sexes · Updated Sep 21, 2026 · NCT07830225Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04038619Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT05267626R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
RecruitingPhase 1
Ages 18 to 80 · All sexes · Updated Sep 18, 2026 · NCT06398418BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT04752826A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07492680Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
RecruitingPhase 2
Ages 18 to 120 · All sexes · Updated Sep 16, 2026 · NCT05155033From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.